CN115028636A - 三唑并嘧啶化合物和其用于治疗癌症的用途 - Google Patents

三唑并嘧啶化合物和其用于治疗癌症的用途 Download PDF

Info

Publication number
CN115028636A
CN115028636A CN202210528891.2A CN202210528891A CN115028636A CN 115028636 A CN115028636 A CN 115028636A CN 202210528891 A CN202210528891 A CN 202210528891A CN 115028636 A CN115028636 A CN 115028636A
Authority
CN
China
Prior art keywords
methyl
trimethyl
triazolo
pyrrolidin
room temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210528891.2A
Other languages
English (en)
Chinese (zh)
Inventor
F·W·高德柏格
A·K·T·丁
G·M·拉蒙特
D·巴塔
J·G·柯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dizhe Jiangsu Pharmaceutical Co ltd
Original Assignee
Dizhe Jiangsu Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizhe Jiangsu Pharmaceutical Co ltd filed Critical Dizhe Jiangsu Pharmaceutical Co ltd
Publication of CN115028636A publication Critical patent/CN115028636A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202210528891.2A 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途 Pending CN115028636A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862670075P 2018-05-11 2018-05-11
US62/670,075 2018-05-11
CN201980046079.2A CN112469721B (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途
PCT/EP2019/062020 WO2019215316A1 (en) 2018-05-11 2019-05-10 Triazolopyrimidine compounds and their use in treating cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980046079.2A Division CN112469721B (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途

Publications (1)

Publication Number Publication Date
CN115028636A true CN115028636A (zh) 2022-09-09

Family

ID=66484070

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210528891.2A Pending CN115028636A (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途
CN202210528893.1A Active CN115028637B (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途
CN201980046079.2A Active CN112469721B (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210528893.1A Active CN115028637B (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途
CN201980046079.2A Active CN112469721B (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途

Country Status (16)

Country Link
US (3) US11084827B2 (https=)
EP (2) EP3790879B1 (https=)
JP (1) JP7418353B2 (https=)
KR (1) KR102863374B1 (https=)
CN (3) CN115028636A (https=)
AR (1) AR115384A1 (https=)
AU (1) AU2019264826B2 (https=)
BR (1) BR112020023068A2 (https=)
CA (1) CA3099579A1 (https=)
DK (1) DK3790879T3 (https=)
ES (1) ES2927244T3 (https=)
MX (1) MX2020012058A (https=)
PT (1) PT3790879T (https=)
TW (1) TWI823932B (https=)
UY (1) UY38228A (https=)
WO (1) WO2019215316A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途
MX2022010634A (es) * 2020-02-28 2023-01-19 Remix Therapeutics Inc Derivados de piridazina para modular el empalme de acidos nucleicos.
WO2021236893A1 (en) * 2020-05-21 2021-11-25 Teon Therapeutics, Inc. Monocarboxylic acid transporter 4 (mct4) modulators and uses thereof
WO2021249969A1 (en) * 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
AU2021372815A1 (en) 2020-11-02 2023-06-22 Ares Trading S.A. Combination treatment of cancer
WO2022243574A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use
WO2022243573A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use
CN120699024A (zh) * 2024-03-25 2025-09-26 北京福元医药股份有限公司 Mct4抑制剂及其药物组合物和用途
CN121735952A (zh) * 2026-02-26 2026-03-27 山东齐都药业有限公司 维立西呱的制备方法及其中间产物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072746A1 (en) * 2001-10-16 2004-04-15 Michael Sullivan Inhibitors of monocarboxylate transport
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
DE102005034905A1 (de) 2005-07-26 2007-02-01 Federal-Mogul Nürnberg GmbH Verfahren zur Herstellung eines Kolbens für einen Verbrennungsmotor sowie Kolben für einen Verbrennungsmotor
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
WO2016118823A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Pteridine dione monocarboxylate transporter inhibitors
CA2974697A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Pyrimidine-2,4-(1h,3h)-dione derivatives and pharmaceutical compositions thereof and their use as inhibitors of monocarboxylate transporters
EP3942934A1 (en) * 2015-06-12 2022-01-26 Vettore, LLC Mct4 inhibitors for treating disease
US20190135747A1 (en) * 2016-05-12 2019-05-09 Regents Of The University Of Minnesota Indole and indazole cyanocinnamate compounds and therapeutic uses thereof
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
AR115384A1 (es) 2021-01-13
US11851432B2 (en) 2023-12-26
AU2019264826B2 (en) 2024-05-23
MX2020012058A (es) 2021-02-26
KR102863374B1 (ko) 2025-09-22
ES2927244T3 (es) 2022-11-03
US11084827B2 (en) 2021-08-10
TWI823932B (zh) 2023-12-01
US20240217980A1 (en) 2024-07-04
JP2021523177A (ja) 2021-09-02
DK3790879T3 (da) 2022-08-29
CN112469721B (zh) 2022-06-07
BR112020023068A2 (pt) 2021-02-09
PT3790879T (pt) 2022-08-26
US20210087196A1 (en) 2021-03-25
US12503473B2 (en) 2025-12-23
AU2019264826A1 (en) 2020-11-26
CN115028637B (zh) 2024-03-22
EP3790879A1 (en) 2021-03-17
TW202015674A (zh) 2020-05-01
KR20210013078A (ko) 2021-02-03
EP3790879B1 (en) 2022-06-29
CA3099579A1 (en) 2019-11-14
EP4134368A1 (en) 2023-02-15
WO2019215316A1 (en) 2019-11-14
CN115028637A (zh) 2022-09-09
JP7418353B2 (ja) 2024-01-19
CN112469721A (zh) 2021-03-09
US20210340150A1 (en) 2021-11-04
UY38228A (es) 2019-10-31

Similar Documents

Publication Publication Date Title
CN112469721B (zh) 三唑并嘧啶化合物和其用于治疗癌症的用途
CN111936498B (zh) N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
CN114845711A (zh) Raf激酶的抑制剂
US20220169643A1 (en) Estrogen receptor degrading protacs
KR20240053589A (ko) 이중 기능성 키메라 헤테로 고리 화합물 및 이의 안드로겐 수용체 분해제로서의 용도
CN113348170A (zh) 联苯类衍生物抑制剂、其制备方法和应用
EP2867233A1 (en) 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
JP2023533003A (ja) ヘテロ環式免疫調節物質
KR20240021925A (ko) Cdk 억제제로서 치환된 피라졸로[1,5-a]피리미딘-7-아민 화합물 및 이들의 치료적 용도
CN115298182A (zh) 作为kcc2调节剂的稠合的嘧啶化合物
HK40080418A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40080417A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40047024A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40080417B (zh) 三唑并嘧啶化合物和其用於治疗癌症的用途
RU2793249C2 (ru) Триазолпиримидиновые соединения и их применение в лечении рака
CN115151551B (zh) 作为mcl-1抑制剂的大环吲哚衍生物
HK40088382A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40047025A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40047025B (en) Triazolopyrimidine compounds and their use in treating cancer
TWI910148B (zh) 芳基或雜芳基衍生物
HK40049641A (en) Biphenyl derivative inhibitor, preparation method therefor and use
HK40077347A (zh) Raf激酶的抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080418

Country of ref document: HK